Morgan Stanley initiated coverage on shares of Gilead Sciences (NASDAQ:GILD) in a research note issued on Wednesday, Stock Ratings Network reports. The firm set an “equal weight” rating and a $75.00 price target on the stock. Morgan Stanley’s target price would indicate a potential upside of 5.03% from the company’s current price. Gilead Sciences, Inc. (NASDAQ:GILD) shares after opening at $69.17 moved to $71.00 on last trade day and at the end of the day closed at $70.86. Company price to sales ratio in past twelve months was calculated as 9.73 and price to cash ratio as 51.12. Gilead Sciences, Inc. (NASDAQ:GILD) showed a negative weekly performance of -1.76%.
Rumor has it that Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) is going to be acquired by Jazz Pharmaceuticals (JAZZ), with the latter willing to pay over $20 per share for the company, valuing it at about $3.6 billion. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) shares advanced 1.00% in last trading session and ended the day on $8.06. ARIA return on equity ratio is recorded as -98.50% and its return on assets is -65.80%. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) yearly performance is -55.96%.
Biopharmaceutical Company, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), expects majority of its revenue for the year to come from its flagship drug, Belviq. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) shares moved up 3.28% in last trading session and was closed at $6.30, while trading in range of $6.05 – $6.32. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) year to date (YTD) performance is 7.69%.
Research analysts at Credit Suisse lowered their price objective on shares of Exelixis, Inc. (NASDAQ:EXEL) from $6.00 to $5.00 in a report released on Wednesday, StockRatingsNetwork.com reports. Credit Suisse’s target price suggests a potential upside of 29.53% from the company’s current price. Exelixis, Inc. (NASDAQ:EXEL) weekly performance is -43.54%. On last trading day company shares ended up $3.54. Exelixis, Inc. (NASDAQ:EXEL) distance from 50-day simple moving average (SMA50) is -47.78%. Analysts mean target price for the company is $7.38.
Leave a Reply